Related Experiment Video
Updated: May 28, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Current and Novel Inhibitors of HIV Protease
Jana Pokorná1, Ladislav Machala, Pavlína Rezáčová
1Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, Gilead Sciences and IOCB Research Center, Flemingovo n. 2, 166 10, Prague 6, Czech Republic; E-Mails: jana.pokorna@uochb.cas.cz (J.P.); pavlina.rezacova@uochb.cas.cz (P.R.).
Abstract:
The design, development and clinical success of HIV protease inhibitors represent one of the most remarkable achievements of molecular medicine. This review describes all nine currently available FDA-approved protease inhibitors, discusses their pharmacokinetic properties, off-target activities, side-effects, and resistance profiles. The compounds in the various stages of clinical development are also introduced, as well as alternative approaches, aiming at other functional domains of HIV PR. The potential of these novel compounds to open new way to the rational drug design of human viruses is critically assessed.
Related Concept Videos
Inhibitors of Virion Maturation and Assembly
Inhibitors of Viral Protein Synthesis
Antiviral Nucleoside Inhibitors
Inhibitors Of Virion Release
Inhibitors of Bacterial Protein Synthesis
Retrovirus Life Cycles

